ZIVO Bioscience is initiating a second collaborative study with the University of Delaware to further investigate the potential of its proprietary algal-derived ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) in poultry. A prior study showed promising results, demonstrating a significant reduction in viral shedding and delayed disease transmission. This follow-up research aims to refine formulations and treatment protocols for practical application in poultry production.

This research holds considerable potential for the poultry industry, which faces ongoing challenges in managing avian influenza. Effective, non-antibiotic solutions are increasingly crucial given rising concerns about antibiotic resistance and the economic impact of LPAI outbreaks. ZIVO’s approach, if successful, could offer a valuable new tool for disease control and enhance overall flock health and productivity. The interest from global animal health companies further underscores the potential market demand for such a product.

The new study builds on previous positive findings in both avian influenza and coccidiosis research. ZIVO is focusing on optimizing the application of its algal-derived active ingredients within real-world poultry production settings. This focus on practical application suggests a commitment to developing a commercially viable product.

This next stage of research represents a critical step towards potentially bringing a novel LPAI mitigation solution to market. The results of this study will likely influence future research directions, potential partnerships, and ultimately, the commercial viability of ZIVO’s algal-based approach to poultry health. The outcome may shift the paradigm of avian influenza management within the poultry industry, offering a potentially more sustainable and cost-effective alternative to existing methods.

Source link: http://www.businesswire.com/news/home/20250206639313/en/ZIVO-Bioscience-Plans-New-Study-with-University-of-Delaware-to-Combat-Avian-Influenza-in-Poultry

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.